1 / 33

Pharmacologic management of UA/NSTEMI

Pharmacologic management of UA/NSTEMI. Nogury, M.S., Pharm.D. Internal Medicine In-service . UA/NSTEMI. A clinical syndrome usually caused by atherosclerotic CAD Associated with an increased risk of cardiac death and MI UA vs. NSTEMI

rendor
Download Presentation

Pharmacologic management of UA/NSTEMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacologic management of UA/NSTEMI Nogury, M.S., Pharm.D. Internal Medicine In-service

  2. UA/NSTEMI • A clinical syndrome usually caused by atherosclerotic CAD • Associated with an increased risk of cardiac death and MI • UA vs. NSTEMI • Ischemia in NSTEMI is severe enough to have detectable cardiac markers

  3. Pathogenesis of UA/NSTEMI • Non-occlusive thrombus on pre-existing plaque • Dynamic obstruction (coronary spasm or vasoconstriction) • Progressive mechanical obstruction • Inflammation and/or infection • Secondary UA

  4. Presentation of UA/NSTEMI • Rest angina: usually > 20 min • New onset angina: ≥CCS class III • Increasing angina: more frequent, longer in duration, or lower in threshold • Should determine short-term risk of death or nonfatal MI based on history, character of pain, clinical findings, ECG changes, and presence of cardiac markers

  5. Pharmacologic treatment • Goals • Immediate relief of ischemia and the prevention of serious adverse outcomes • Options • Anti-ischemic drugs • nitrates, morphine, beta-blockers • Anti-platelet drugs & anticoagulants • aspirin, clopidogrel, heparin, LMWH, GPIIb/IIIa antagonists • Risk-modifying drugs • lipid lowering agents (statins)

  6. Nitrates • MOA: ↓ preload & afterload → ↓ MVO2 • Indicated when chest pain despite SL NTG x 3 • Administered by either IV, topical, or oral route • IV NTG: initiated with 10 μg/min with increment of 10 μg/min q3-5min up to 200 μg/min

  7. Nitrates-continued • Once pt stabilized, may convert to nitropaste and subsequently po isosorbide • Does not decrease mortality in AMI • ADRs: Hypotension, headache, reflex tachycardia • Tolerance can develop • Monitoring parameters: SBP - ≥110 mmHg in normotensive pts - ≤ 25% decrease in MAP in hypertensive pts

  8. Morphine sulfate • Has analgesic, anxiolytic and favorable hemodynamic effects • Indicated • when pain despite SL NTG x 3 • recurrent symptoms despite adequate anti-ischemic therapy • 1-5 mg IV q5-30 min

  9. Morphine sulfate-cont’d • ADRs • Hypotension, nausea/vomiting, respiratory depression • Naloxone (0.4-2.0 mg IV) for morphine overdose • Meperidine for morphine allergy pt

  10. Beta-blockers • Has anti-arrhythmic, anti-ischemic, and antihypertensive properties • 13% reduction in MI among pts with UA • Unless contraindication exists, all pts should receive intravenous followed by oral beta-blockers • CIs: marked 1st degree AV block, 2nd and 3rd degree AV block, severe LV dysfn with CHF

  11. Beta-blockers cont’d • Goal: resting HR < 60 bpm • Do not use β-blockers with ISA • Should be held when SBP < 90 mmHg or HR < 50 bpm, decompensated CHF • ADRs: bradycardia, hypotension, bronchospasm • Dosing • Metoprolol: 5 mg IV q 5 min x 3; followed by 50 mg po q6h for 48 hrs

  12. Beta-blockers cont’d • Chronic oral therapy

  13. Calcium antagonists • ↓ afterload (& ↓ conduction velocity) • Verapamil or diltiazem is indicated when beta-blockers are contraindicated • Dihydropyridine do not have consistent beneficial effect on mortality or MI recurrence • Do not use immediate-release, short-acting nifedipine b/c of ↑ in mortality

  14. Aspirin • Irreversibly inhibits COX-dependent platelet activation at low dose (>75 mg/d) • ↓ mortality and rate of MI, stroke and vascular death • All pts should receive aspirin unless contraindication exists • At first sign of CP, chew and swallow 325 mg x 1, then continue 81-325 mg qd for life

  15. Aspirin-cont’d • Contraindications • Intolerance, allergy, active bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active peptic ulcer, GI or GU bleeding

  16. Clopidogrel • Irreversible ADP antagonist • Takes several days to show complete effect • At least as effective as ASA • Dosing • 300 mg loading followed by 75 mg po QD

  17. Clopidogrel-cont’d • Indications • when ASA is contraindicated • Should be added to ASA ASAP on admission and given for at least 1 mo and for up to 9 mo in pts with no early intervention plan • Should be started and continued for at least 1 mo and for up to 9 mo in pts with PCI planned • Should be held for at least 5 days, preferably 7 days, in pts when CABG is planned

  18. Unfractionated heparin • Complexes with antithrombin III to inhibit thrombin, factors Xa, XIa, XIIa and IXa • Early admin. ↓ the incidence of AMI • Should be added to ASA + clopidogrel • Dosing • 60~70 U/kg bolus (max: 5,000 U) followed by 12~15 U/kg/h (max: 1,000 U/kg/h) • Duration: undefined for asymptomatic pts or continued until an invasive intervention in symptomatic pts

  19. Unfractionated heparin-cont’d • Monitoring parameters • aPTT at 1.5-2.5 times control values • aPTT q6h after initiating therapy and after subsequent dosage adjustment • Once 2 consecutive aPPTs within the target, aPTT q24h • PLT, Hct/Hgb • ADRs • Thrombocytopenia: not-dose and not-duration dependent

  20. Low Molecular Weight Heparin • More selective for factor Xa compared to thrombin • Advantages: • More predictable and sustained anticoagulation b/c of dose-independent clearance with longer t1/2 • Do not usually require lab monitoring activity • Enoxaparin may be superior to UFH in the treatment of UA

  21. Low Molecular Weight Heparin-cont’d • Enoxaparin dosing: 1 mg/kg SC q12h • Should Not be used • CrCl <30 ml/min • Very obese: >120 kg • May monitor antifactor Xa 4hr after the admin. • UFH is preferred in pts likely to undergo CABG within 24h, b/c of the reversibility of anticoagulating effect • LMWH should be held at least 8 hr before the intervention

  22. GPIIb/IIIa antagonists • Inhibits platelet aggregation by blocking GPIIb/IIIa receptor to which fibrinogen binds • Abciximab, eptifibatide, tirofiban • Indications • Should be given, in addition to ASA, clopidogrel and UFH, to pts when catheterization and PCI are planned • Should be given, in addition to ASA and UFH or LMWH, to pts with continuing ischemia or an elevated troponin

  23. GPIIb/IIIa antagonists Monitor plt 2-4 hr after bolus and then daily (Reopro), 6 hr after bolus and then daily (Integrelin & Aggrastat)

  24. ACE I • ↓ LV dysfn and slow progression to HF by preventing LV remodelling • ↓ mortality in pts • with AMI • who recently had an MI, and have LV dysfn • in diabetic pts with LV dysfn • in a broad spectrum of pts with high-risk chronic CAD, including pts with normal LV fn • Initiated after ASA + clopidogrel and beta-blockers when pt is hemodynamically stable

  25. ACE I-cont’d • Contraindications • Hypotension • Bilateral renal artery stenosis • Acute renal failure • Angioedema • Pregnancy • Hyperkalemia • ADRs • Hyperkalemia, angioedema, dry cough, hypotension

  26. ACE I-cont’d

  27. Lipid lowering agents (Statins) • Inhibits HMG-CoA reductase, a rate limiting enzyme of cholesterol biosynthesis • ↓ rate of AMI • Goal • LDL < 100 mg/dL • HDL > 40 mg/dL • Should be initiated 24-96 hr after admission • May provide benefit independent of lipid lowering effect

  28. Other modifiable risks • Hypertension • Smoking • Diabetes

  29. Typical discharge regimen • SL NTG • Clopidogrel + ASA • Beta-blocker • ACE I • Statin

  30. References • Braunwald et al, ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. 2002 www.acc.org/clinical/guidlines/unstable/unstable.pdf

  31. Abbreviations • UA: unstable angina • NSTEMI: non ST segment elevation myocardial infarction • CAD: coronary artery diseases • MI: myocardial infarction • CCS: Canadian Cardiovascular Society • ECG: electrocardiogram • LMWH: low molecular weight heparin • GPIIb/IIIa: glycoprotein IIb/IIIa • MOA: mechanism of action • MVO2: myocardial wall tension • SL NTG: subligual nitroglycerin • AMI: acute myocardial infarction • ADRs: adverse drug reactions • SBP: systolic blood pressure • MAP: mean arterial blood pressure

  32. Abbreviations • Pt(s): patient(s) • CIs: contraindications • AV: atrioventricular • LV: left ventricular • Dysfn: dysfunction • CHF: congestive heart failure • HR: heart rate • ISA: intrinsic sympathomimetic activity • bpm: beat per minute • b/c: because • COX: cyclooxygenase • CP: chest pain • GI: gastrointestinal • GU: genitourinary • ADP: adenosine diphosphate • ASA: aspirin • ASAP: as soon as possible

  33. Abbreviations • PCI: percutaneous coronary intervention • CABG: coronary artery bypass graft • aPTT: activated partial thrombin time • PLT: platelet • Hct: hematocrit • Hgb: hemoglobin • UFH: unfractionated heparin • CrCl: creatinine clearance • HF: heart failure • HMG: hydroxymethylglutaryl • LDL: low density lipoprotein • HDL: high density lipoprotein

More Related